R. Kaiser

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014 · 948 citations · Full text

Medicine, Oncology, Pharmacology +11

Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes

R. Kaiser, Orhan Sezer, Anja Papies et al. · Journal of Clinical Oncology · 2002 · 254 citations

Medicine, Pharmacology, Pharmacotherapy +17

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

K. Mross, Martin Štefanič, Daniela Gmehling et al. · Clinical Cancer Research · 2009 · 169 citations

Medicine, Oncology, Pharmacology +16

Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients

Pierre‐Benoit Tremblay, R. Kaiser, Orhan Sezer et al. · Journal of Clinical Oncology · 2003 · 161 citations

Medicine, Oncology, Pharmacology +17

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

K. Mross, Annette Frost, Simone Steinbild et al. · Journal of Clinical Oncology · 2008 · 158 citations · Full text

Pharmacy, Oncology, Pharmacology +14